Please assess the completion status of the following clinical trial:

Trial Title: Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* perimenopausal or early postmenopausal women aged 45-60 years old~* not on HRT for at least one year before the initiation of the study~* maintaining normal exercise level (\<7 h/wk) and willing to avoid exercise 24-h prior to blood and stool sampling and 12-h prior to bone measurements~* willing to ingest a dietary BC supplement or placebo (up to 900 mg/day, two 450 mg capsules) as well as 400 mg calcium and 500 IU vitamin D daily~* willing to avoid other dietary supplements for the duration of the study~* willing to avoid intake of foods extremely rich in anthocyanins and fermented dairy products containing viable Bifidobacteria or Lactobacilli~* willing to have 3 blood draws, 2 stool collections, and 2 bone scans~* willing to take urine pregnancy test if they are perimenopausal.~Exclusion Criteria:~* those with metabolic bone disease, renal disease, cancer, cardiovascular disease, diabetes mellitus, respiratory disease, gastrointestinal disease, liver disease or other chronic diseases~* those with hypertension or on drugs that lower blood pressure~* those with planned surgery during the study period or within 2 weeks of ending the intervention~* taking medications that alter bleeding (such as antiplatelets or anticoagulants) or those with a bleeding disorder~* taking a phenothiazine drug (most commonly used for nausea or mental health conditions)~* having a sensitivity or allergy to any of ingredients for the placebo (rice powder) and calcium/D supplement (calcium citrate, polyethylene glycol, croscarmellose sodium, hydroxypropyl methylcellulose, magnesium stearate, oligofructose enriched inulin, propylene glycol dicaprylate/dicaprate, talc, titanium dioxide, vitamin D3)~* heavy smokers (\>20 cigarettes/day)~* perimenopausal women with any chance or plan of pregnancy~* taking prescription medications known to alter bone and Ca metabolism such as calcitonin, bisphosphonates, raloxifene within 3 months before the start of the study~* taking anabolic agents such as parathyroid hormone, growth hormone, or steroids within 3 months before the start of the study~* planning any procedure that includes iodine, barium or nuclear medicine isotopes in next 7 months~* alcohol consumption exceeding 2 drinks/day (approximately 14 g ethanol per drink) or a total of 12/week~* UConn students and/or employees who any key personnel teach or who report to any key personnel~* study key personnel, spouses of key personnel, or dependents/relatives of any key personnel.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- low-BC Group (Type: ACTIVE_COMPARATOR): consume: 1) one tablet containing 392 mg blackcurrant (BC) extract per capsule and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
- high-BC Group (Type: ACTIVE_COMPARATOR): consume: 1) two capsules containing 392 mg BC extract per tablet (total 784 mg/day) and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
- Control Group (Type: PLACEBO_COMPARATOR): consume: 1) one placebo capsule and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete